加载中
NASDAQHealthcareBiotechnology
最新数据
US$18.7633
−US$0.6467 · -3.33%
Acadia Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.
常规交易时段
US$18.7633
−US$0.6467 · -3.33%
盘中时间采用ET。市场数据可能有所延迟。
Acadia Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.
日内区间
当前US$18.7633
52周区间
当前US$18.7633
盘中时间采用ET。市场数据可能有所延迟。
Acadia Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.
日内区间
当前US$18.7633
52周区间
当前US$18.7633
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 10.72亿 USD | 9.58亿 USD | 7.26亿 USD | 5.17亿 USD | 4.84亿 USD |
| 销货成本 | 8899.8万 USD | 8184.1万 USD | 4573.1万 USD | 1016.6万 USD | 1914.1万 USD |
| 毛利 | 9.83亿 USD | 8.76亿 USD | 6.81亿 USD | 5.07亿 USD | 4.65亿 USD |
| 研究与开发 | 3.29亿 USD | 3.03亿 USD | 3.52亿 USD | 3.62亿 USD | 2.39亿 USD |
| 销售、一般及管理费用 | 5.49亿 USD | 4.88亿 USD | 4.02亿 USD | 3.69亿 USD | 3.96亿 USD |
| 营业费用 | 8.78亿 USD | 6.45亿 USD | 7.54亿 USD | 7.31亿 USD | 6.35亿 USD |
| 利息收入 | 3172.2万 USD | 2545.8万 USD | 1723.4万 USD | 661万 USD | 59.1万 USD |
| 折旧和摊销 | 1176万 USD | 1588.3万 USD | 555.2万 USD | 202.6万 USD | 334.4万 USD |
| 营业利润 | 1.05亿 USD | 2.31亿 USD | −7337.9万 USD | −2.24亿 USD | −1.7亿 USD |
| 净利润 | 3.91亿 USD | 2.26亿 USD | −6128.6万 USD | −2.16亿 USD | −1.68亿 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$29.95
上涨空间 59.62%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1.18亿0.01%2.3万亿 USD0.03%US$380.88-0.18%
Vanguard Morningstar Small-Cap ETFVB8552.4万0.05%1853亿 USD0.03%US$287.02-0.40%
iShares Russell 2000 ETFIWM6400.3万0.08%787.4亿 USD0.19%US$276.38-0.55%
Vanguard Morningstar Small-Cap Growth ETFVBK4912.76万0.11%447亿 USD0.05%US$337.68-0.94%
State Street SPDR S&P Biotech ETFXBI4815.02万0.49%103.03亿 USD0.35%US$148.36-2.01%
Vanguard Extended Market ETFVXF4259.11万0.04%954亿 USD0.05%US$232.05-0.63%
iShares Biotechnology ETFIBB2572.49万0.24%108.2亿 USD0.44%US$201.64-1.28%
Dimensional - US Small Cap ETFDFAS2395.25万0.07%338.04亿 USD0.31%US$77.99-0.23%Vanguard Morningstar Total Stock Market ETFVTIVanguard Morningstar Small-Cap ETFVBiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap Growth ETFVBKState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBDimensional - US Small Cap ETFDFASAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
